Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs VICI Properties Inc (VICI) Price & Performance

Inovio Pharmaceuticals IncTrade
VICI Properties IncTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs VICI Properties Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M), while VICI Properties Inc trades at $26.09 (market cap $28.61B). The key difference: VICI Properties Inc is far larger — about 364.2× Inovio Pharmaceuticals Inc's market cap, and VICI Properties Inc pays a 6.93% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

INOVICI
Market Cap
$78.55M$28.61B
Sector
HealthReal Estate
52-Week High
$2.87$33.78
52-Week Low
$0.66$25.94
Enterprise Value
$49.56M$46.16B
Dividend Yield
6.93%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.

The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.

VICI Properties Inc

VICI Properties trades at $26.03, down 0.17% on the day, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 10.07, net income margin of 67.5%, and a recent dividend of $0.45 paid in July 2026. Q2 2026 earnings saw an EPS miss at $0.48 versus $0.713 expected, though revenue beat forecasts, and the company raised its AFFO guidance.

Analyst consensus is strongly bullish with a $29.83 price target and 76.9% buy ratings, highlighting the 6.6% dividend yield and solid cash flow. Key risks include high debt levels, interest expense pressure, and uncertainty from the Caesars acquisition overhang, but the REIT's tangible assets and oligopoly advantages support long-term income appeal.

Returns comparison

Trailing returns across standard periods

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO

About VICI Properties Inc

VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.

Read more on VICI